Novo Nordisk receives FDA approval for Norditropin® FlexPro® 30 mg/3.0 mL
Novo Nordisk announced the FDA approval of Norditropin® (somatropin [rDNA origin] injection) FlexPro® 30 mg/3.0 mL, a prefilled injection pen for patients with growth hormone-related disorders. The FlexPro® 30 mg/3.0 mL device complements the portfolio of Norditropin FlexPro® products now available. January 26, 2015